Thalidomide for previously untreated indolent or smoldering multiple myeloma. - Wikidata - awgldk - TriplyDB

Thalidomide for previously untreated indolent or smoldering multiple myeloma.

Thalidomide for previously untreated indolent or smoldering multiple myeloma.

http://www.wikidata.org/entity/Q33146651

about

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance Does my patient with a serum monoclonal spike have multiple myeloma?Smoldering multiple myeloma requiring treatment: time for a new definition?Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis.Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications.Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.Management of thalidomide toxicity.Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma How I treat smoldering multiple myeloma.Dilemmas in treating smoldering multiple myeloma.Thalidomide for erythema nodosum leprosum and other applications.Monoclonal gammopathies of undetermined significance: a review.Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma.Thalidomide and its derivatives: new promise for multiple myeloma.Thalidomide for the treatment of multiple myeloma.Targeted therapy in multiple myeloma.Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.Angiogenesis and hematological malignancies.CD4+CD25+ cells in multiple myeloma related renal impairment.Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis.Angiogenic inhibitors: a new therapeutic strategy in oncology.Investigational treatments for multiple myeloma.Review of thalidomide in the treatment of newly diagnosed multiple myeloma.54-year-old woman with fatigue, back pain, and hypercalcemia Smoldering multiple myeloma: present position and potential promises.Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?The road to cure in multiple myeloma starts with smoldering disease.Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others.Novel therapies delay the progression of smoldering multiple myeloma: Case report and discussion.Thalidomide effects in the post-transplantation setting in patients with multiple myeloma.Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma.Genomic analysis of high-risk smoldering multiple myeloma.The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma.Thalidomide as initial therapy for early-stage myeloma.Thalidomide therapy induces response in relapsed mantle cell lymphoma.Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow transplantation for T-ALL.

P2860

Q24607241-3AE7CE73-80CE-42B3-92FF-F9459AF4BE39 Q24651269-1F69A9E8-D578-4C0E-8844-7928E3F6C94F Q24669898-8BF7D05D-6F15-493A-ACF1-10E35977F1E3 Q26821981-1C675ADA-3D4A-4952-A942-63549053F47E Q26996579-41D6CE41-3CA7-4A7B-9D6B-64D773C95AEC Q33151135-54DA98CF-8CFB-4A6B-AC56-6C138459116C Q33632270-9898D2A6-5DE3-45E8-9A7E-43B1C832F4F8 Q34184698-97365136-1B82-4AA4-908E-1289929907F2 Q34316559-FD49A3C2-5380-4E0B-9913-0995342CBBEF Q34343991-D67ABF61-A778-44A2-A1BA-B55B0B46BCE9 Q34497797-E9154775-0BDA-4D3A-87B0-0CE4FCB6F46C Q34580094-1DADC3A0-EAC0-4FA5-A04D-9E21940A1519 Q34716500-AD6B8404-8933-41FC-B8D5-7B01969E7402 Q35101473-F52032C7-9B5F-43C6-9682-DF11F6B69BCA Q35170927-200D49E7-8304-4980-B373-9A939CD25C56 Q35175287-E8AD5FDD-E995-4875-8B64-B5283B30BC34 Q35210732-FEA8A202-6D1E-439A-AC97-9DB9FC3BE110 Q35569462-F711FEDF-78D5-4A64-AD69-EE3EA1FFA930 Q35870500-91797D95-C2CC-4CD2-ACAF-B5A44258A89B Q36108614-0B467297-DFA6-4662-AF41-C3B3F33C8793 Q36171864-88EA58D6-33D0-4C91-9C84-E977E1F0EA7C Q36194525-9764F21B-82B2-4D32-BC7A-40EAB99C07BE Q36275650-6E4886BE-B9B4-4AB8-9E8F-45B1CA7EEB3C Q36303471-A77A75DF-748A-43B4-B8A2-1D32925EEACA Q36306264-C1FDB7F1-CD3B-457E-A70D-93947EC6B4CB Q36654336-133223B7-A687-47E1-BB88-C86AA0F2F7EB Q37160347-454C63F5-884D-435B-83CF-954FDB58DA51 Q37454464-461BDB5D-994C-422E-91A3-0155E6F01BA9 Q38151230-0CC8FC9F-1CE1-430F-9F0B-5CF853B14B7D Q38190593-CA59CC69-99F1-47EA-BDCF-81313AAA365C Q38494968-44CB8BCC-3FBE-4D65-B26B-93D666C1E585 Q38649220-D9627568-1808-4A07-B9E7-01F1BF93080A Q39689809-1118A02B-A1F7-4DC8-809C-90E8C808378D Q40531242-BA787C02-664E-4C81-8B22-C99C05AA9281 Q41591687-C856B6AB-6F89-434C-9D1C-DABE3EF89B94 Q41847877-9E4BD5B2-9C8C-438F-9032-F7E1B642D0B9 Q44177889-F42A84AD-CB00-4A2A-9025-53328B146866 Q44394897-2A9C1134-DD4F-4F77-B355-7EBB57AFE3ED Q44582819-B279DA4F-4B30-4C62-8672-F8CC9B7D231E Q44598673-F149AFC5-6B58-47F3-97DB-1233E5CCBEA5

P2860

Thalidomide for previously untreated indolent or smoldering multiple myeloma.

http://www.wikidata.org/entity/Q33146651

description

2001 nî lūn-bûn

@nan

2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Thalidomide for previously untreated indolent or smoldering multiple myeloma.

@ast

Thalidomide for previously untreated indolent or smoldering multiple myeloma.

@en

type

label

Thalidomide for previously untreated indolent or smoldering multiple myeloma.

@ast

Thalidomide for previously untreated indolent or smoldering multiple myeloma.

@en

prefLabel

Thalidomide for previously untreated indolent or smoldering multiple myeloma.

@ast

Thalidomide for previously untreated indolent or smoldering multiple myeloma.

@en

P1433

Q33146651-A22FD429-0C31-4041-8749-7BA3938BAC32

P1476

Q33146651-36C706F1-7F54-424A-89AB-7B9C6A9D3D73

P2093

Q33146651-0E7C9CA6-BCAD-44CB-88B8-71FDA250B70F

Q33146651-299D05A1-E4BF-4828-8164-4E39FA5BB5B6

Q33146651-2F178451-CFD8-42DC-BD15-0C19F8F780EE

Q33146651-4266CE7B-9D10-479C-B47A-5DBF3A69AF68

Q33146651-4F68C675-0FD8-4912-B128-A68FB66B792B

Q33146651-7EE346E4-C42C-47F2-8A8A-F889DAD78EDB

Q33146651-A6524117-7DB9-4B90-A029-AE2478FAECA2

Q33146651-A679F4B5-E183-4EEA-AD22-C9F35C7DC334

Q33146651-D2B0F3FD-CB41-414D-9FF1-61D405C728F7

Q33146651-E21F8EE9-9501-4EFC-8223-61A6E48E3DED

P2888

Q33146651-5B5E6F59-C1D0-45FB-8AB9-99D7D60048BE

P304

Q33146651-4608F4A0-DF10-4BA1-BF8A-86E07DE4CED5

P31

Q33146651-FA399799-B0B1-4D12-B105-D7812987F0CF

P356

Q33146651-8E44470A-7B7B-4E8A-8389-8BBAB9BD0A14

P433

Q33146651-340C187F-A406-4B67-A9C5-A73ED8421C2D

P478

Q33146651-128CF985-408A-414E-BFE2-2689D4976FC8

P577

Q33146651-E28D1372-BC95-4502-9B0D-DD80627EEE97

P5875

Q33146651-E2AC442A-DC67-4129-9EFA-02C03D858D8E

P6179

Q33146651-41FA9F13-B920-46FD-B2DD-F711DB9F177C

P698

Q33146651-295F59FD-24AB-4CAE-862F-6AB792CFF298

P921

Q33146651-EF8AA84A-9480-4678-8B43-C3F7A81E4648

P356

P1433

P1476

Thalidomide for previously untreated indolent or smoldering multiple myeloma.

@en

P2093

Dispenzieri A

http://www.w3.org/2001/XMLSchema#string

Fonseca R

http://www.w3.org/2001/XMLSchema#string

Gertz MA

http://www.w3.org/2001/XMLSchema#string

Geyer S

http://www.w3.org/2001/XMLSchema#string

Greipp PR

http://www.w3.org/2001/XMLSchema#string

Kyle RA

http://www.w3.org/2001/XMLSchema#string

Lacy MQ

http://www.w3.org/2001/XMLSchema#string

Lust JA

http://www.w3.org/2001/XMLSchema#string

Rajkumar SV

http://www.w3.org/2001/XMLSchema#string

Witzig TE

http://www.w3.org/2001/XMLSchema#string

P2888

P304

1274-1276

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.LEU.2402183

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2001-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11861631

http://www.w3.org/2001/XMLSchema#string

P6179

1026754679

http://www.w3.org/2001/XMLSchema#string

P698

11480571

http://www.w3.org/2001/XMLSchema#string

P921